SCINAI Ends PC111 Arrangements to Refocus on NanoAb and CDMO Work

Scinai says it has concluded its PC111 arrangements and will redirect capital to its NanoAb platform and expanding CDMO business.

Share
Scinai Immunotherapeutics chief executive Amir Reichman.
Source: Wikimedia